<p>Nektar Therapeutics（納斯達克股票代碼：NKTR - 獲取免費報告）於週四發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$1.85），超出市場普遍預期的（$2.85）$1.00，FiscalAI 報道。Nektar Therapeutics 的淨利潤率為負 163.17%，股本回報率為負 631.43%。該公司本季度的收入為 1179 萬美元，而市場普遍預期為 1020 萬美元。</p>
<p>獲取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
<h2>Nektar Therapeutics 股票表現</h2>
<ul>
<li>3 只具有爆炸性增長趨勢的看漲生物科技股票</li>
</ul>
<p>週五午盤交易中，NKTR 上漲了$0.85，達到了$55.97。該公司的交易量為 854,201 股，而其平均交易量為 906,206 股。該公司的市值為 10.6 億美元，市盈率為-6.36，貝塔值為 1.19。該公司的 50 日簡單移動平均線為$54.43，200 日簡單移動平均線為$30.79。Nektar Therapeutics 的 12 個月低點為$6.45，12 個月高點為$66.92。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席執行官 Howard W. Robin 於 9 月 9 日星期二出售了 6,666 股公司的股票。股票以平均價格$46.69 出售，總交易額為$311,235.54。交易後，首席執行官持有 49,342 股公司的股票，價值$2,303,777.98。這代表着其持股比例減少了 11.90%。該出售在與 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Jonathan Zalevsky 於 9 月 4 日星期四出售了 1,721 股公司的股票。股票以平均價格$33.52 出售，總交易額為$57,687.92。交易後，該內部人士持有 17,462 股公司的股票，價值約為$585,326.24。該交易使其持股比例減少了 8.97%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 25,178 股公司股票，價值$938,776。目前，5.25% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>生物科技催化劑警報：NKTR、CDTX 和 WGS 大幅上漲</li>
</ul>
<p>幾家對沖基金和其他機構投資者最近買賣了該公司的股票。Vanguard Group Inc.在第三季度將其在 Nektar Therapeutics 的持股增加了 30.0%。Vanguard Group Inc.目前擁有 948,647 股這家生物製藥公司的股票，價值$53,978,000，此前在上個季度又購買了 219,155 股。Envestnet Asset Management Inc.在第三季度獲得了 Nektar Therapeutics 的新頭寸，價值約為$574,000。Marshall Wace LLP 在第二季度購買了 Nektar Therapeutics 的新頭寸，價值$367,000。Rhumbline Advisers 在第一季度將其在 Nektar Therapeutics 的持股增加了 23.3%。Rhumbline Advisers 目前擁有 221,761 股這家生物製藥公司的股票，價值$151,000，此前在上個季度又購買了 41,948 股。最後，AQR Capital Management LLC 在第一季度將其在 Nektar Therapeutics 的持股增加了 336.9%。AQR Capital Management LLC 目前擁有 3,640,851 股這家生物製藥公司的股票，價值$2,463,000，此前在上個季度又購買了 2,807,595 股。機構投資者目前持有該公司 75.88% 的股票。</p>
<h2>分析師評級變動</h2>
<p>多位分析師最近對該股票發佈了報告。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Nektar Therapeutics 股票的 “賣出（d-）” 評級。B. Riley 在 9 月 23 日星期二的研究報告中將 Nektar Therapeutics 的目標價格從$85.00 提高至$105.00，並給予該股票 “買入” 評級。Wall Street Zen 在週六的研究報告中將 Nektar Therapeutics 的評級從 “賣出” 上調至 “持有”。最後，BTIG Research 在 9 月 19 日星期五的報告中重申了 “買入” 評級，並設定了 Nektar Therapeutics 的目標價格為$100.00。五位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司的平均評級為 “適度買入”，共識目標價格為$89.00。</p>
<ul>
<li>Nektar 因藥物試驗數據上漲 157%——還能更高嗎？</li>
</ul>
<p><strong>查看我們對 Nektar Therapeutics 的最新股票分析</strong></p>
<h2>Nektar Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Nektar Therapeutics 是一家生物製藥公司，專注於在美國和國際上發現和開發免疫療法領域的藥物。該公司正在開發 rezpegaldesleukin，這是一種細胞因子 Treg 刺激劑，目前正在進行針對系統性紅斑狼瘡和潰瘍性結腸炎的二期臨牀試驗，以及針對特應性皮炎和銀屑病的二期 b 臨牀試驗；以及 NKTR-255，一種 IL-15 受體激動劑，目前正在進行一期臨牀試驗，以增強免疫系統對抗癌症的自然能力。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Nektar Therapeutics</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>Rivian 的圖表顯示可以購買，但一些分析師仍然表示不建議購買</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>e.l.f.的拋售是購買的好時機，分析師表示</li>
<li>投資者如何從盤後交易中受益</li>
<li>T-Mobile 是最被低估的大型股——是時候購買了嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg"/></p>
<p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Nektar Therapeutics 嗎？</h2>
<p>在考慮 Nektar Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Nektar Therapeutics 並不在名單上。</p>
<p>雖然 Nektar Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

內克塔治療

<p>內克塔治療（NASDAQ:NKTR）公佈了季度財報，每股收益（EPS）為（$1.85），超出預期的（$2.85）$1.00。公司收入為 1179 萬美元，超過了 1020 萬美元的預測。儘管淨利潤率為負的 163.17%，股本回報率為-631.43%，股票價格仍上漲至$55.97。內部交易包括首席執行官霍華德·W·羅賓出售股份，機構投資者持有 75.88% 的股份。分析師評級不一，普遍目標價為$89.00，平均評級為 “適度買入”</p>

<p>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($2.85) by $1.00, FiscalAI reports. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. The business had revenue of $11.79 million during the quarter, compared to the consensus estimate of $10.20 million.</p>
<div class="lb-trans"><p>Nektar Therapeutics（納斯達克股票代碼：NKTR - 獲取免費報告）於週四發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$1.85），超出市場普遍預期的（$2.85）$1.00，FiscalAI 報道。Nektar Therapeutics 的淨利潤率為負 163.17%，股本回報率為負 631.43%。該公司本季度的收入為 1179 萬美元，而市場普遍預期為 1020 萬美元。</p>
</div><p>Get <strong>Nektar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
</div><h2>Nektar Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 股票表現</h2>
</div><ul>
<li>3 Bullish Biotech Stocks With Explosive Growth Trends</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有爆炸性增長趨勢的看漲生物科技股票</li>
</ul>
</div><p>NKTR traded up $0.85 during midday trading on Friday, hitting $55.97. The company had a trading volume of 854,201 shares, compared to its average volume of 906,206. The company has a market capitalization of $1.06 billion, a PE ratio of -6.36 and a beta of 1.19. The firm's 50-day simple moving average is $54.43 and its 200-day simple moving average is $30.79. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $66.92.</p>
<div class="lb-trans"><p>週五午盤交易中，NKTR 上漲了$0.85，達到了$55.97。該公司的交易量為 854,201 股，而其平均交易量為 906,206 股。該公司的市值為 10.6 億美元，市盈率為-6.36，貝塔值為 1.19。該公司的 50 日簡單移動平均線為$54.43，200 日簡單移動平均線為$30.79。Nektar Therapeutics 的 12 個月低點為$6.45，12 個月高點為$66.92。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CEO Howard W. Robin sold 6,666 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $46.69, for a total transaction of $311,235.54. Following the transaction, the chief executive officer owned 49,342 shares of the company's stock, valued at $2,303,777.98. This represents a 11.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Zalevsky sold 1,721 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $33.52, for a total transaction of $57,687.92. Following the transaction, the insider owned 17,462 shares in the company, valued at approximately $585,326.24. The trade was a 8.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 25,178 shares of company stock valued at $938,776. 5.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Howard W. Robin 於 9 月 9 日星期二出售了 6,666 股公司的股票。股票以平均價格$46.69 出售，總交易額為$311,235.54。交易後，首席執行官持有 49,342 股公司的股票，價值$2,303,777.98。這代表着其持股比例減少了 11.90%。該出售在與 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Jonathan Zalevsky 於 9 月 4 日星期四出售了 1,721 股公司的股票。股票以平均價格$33.52 出售，總交易額為$57,687.92。交易後，該內部人士持有 17,462 股公司的股票，價值約為$585,326.24。該交易使其持股比例減少了 8.97%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 25,178 股公司股票，價值$938,776。目前，5.25% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技催化劑警報：NKTR、CDTX 和 WGS 大幅上漲</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Nektar Therapeutics by 30.0% during the third quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company's stock worth $53,978,000 after purchasing an additional 219,155 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in Nektar Therapeutics during the 3rd quarter worth approximately $574,000. Marshall Wace LLP bought a new position in Nektar Therapeutics in the second quarter valued at $367,000. Rhumbline Advisers increased its position in shares of Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after acquiring an additional 41,948 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Institutional investors own 75.88% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了該公司的股票。Vanguard Group Inc.在第三季度將其在 Nektar Therapeutics 的持股增加了 30.0%。Vanguard Group Inc.目前擁有 948,647 股這家生物製藥公司的股票，價值$53,978,000，此前在上個季度又購買了 219,155 股。Envestnet Asset Management Inc.在第三季度獲得了 Nektar Therapeutics 的新頭寸，價值約為$574,000。Marshall Wace LLP 在第二季度購買了 Nektar Therapeutics 的新頭寸，價值$367,000。Rhumbline Advisers 在第一季度將其在 Nektar Therapeutics 的持股增加了 23.3%。Rhumbline Advisers 目前擁有 221,761 股這家生物製藥公司的股票，價值$151,000，此前在上個季度又購買了 41,948 股。最後，AQR Capital Management LLC 在第一季度將其在 Nektar Therapeutics 的持股增加了 336.9%。AQR Capital Management LLC 目前擁有 3,640,851 股這家生物製藥公司的股票，價值$2,463,000，此前在上個季度又購買了 2,807,595 股。機構投資者目前持有該公司 75.88% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nektar Therapeutics in a research report on Wednesday, October 8th. B. Riley boosted their target price on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, September 23rd. Wall Street Zen raised shares of Nektar Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, BTIG Research reissued a &#34;buy&#34; rating and set a $100.00 price objective on shares of Nektar Therapeutics in a report on Friday, September 19th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $89.00.</p>
<div class="lb-trans"><p>多位分析師最近對該股票發佈了報告。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Nektar Therapeutics 股票的 “賣出（d-）” 評級。B. Riley 在 9 月 23 日星期二的研究報告中將 Nektar Therapeutics 的目標價格從$85.00 提高至$105.00，並給予該股票 “買入” 評級。Wall Street Zen 在週六的研究報告中將 Nektar Therapeutics 的評級從 “賣出” 上調至 “持有”。最後，BTIG Research 在 9 月 19 日星期五的報告中重申了 “買入” 評級，並設定了 Nektar Therapeutics 的目標價格為$100.00。五位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司的平均評級為 “適度買入”，共識目標價格為$89.00。</p>
</div><ul>
<li>Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?</li>
</ul>
<div class="lb-trans"><ul>
<li>Nektar 因藥物試驗數據上漲 157%——還能更高嗎？</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on Nektar Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Nektar Therapeutics 的最新股票分析</strong></p>
</div><h2>Nektar Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.</p>
<div class="lb-trans"><p>Nektar Therapeutics 是一家生物製藥公司，專注於在美國和國際上發現和開發免疫療法領域的藥物。該公司正在開發 rezpegaldesleukin，這是一種細胞因子 Treg 刺激劑，目前正在進行針對系統性紅斑狼瘡和潰瘍性結腸炎的二期臨牀試驗，以及針對特應性皮炎和銀屑病的二期 b 臨牀試驗；以及 NKTR-255，一種 IL-15 受體激動劑，目前正在進行一期臨牀試驗，以增強免疫系統對抗癌症的自然能力。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Nektar Therapeutics</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Rivian’s Chart Says Go, But Some Analysts Still Say No</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Nektar Therapeutics</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>Rivian 的圖表顯示可以購買，但一些分析師仍然表示不建議購買</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>e.l.f.的拋售是購買的好時機，分析師表示</li>
<li>投資者如何從盤後交易中受益</li>
<li>T-Mobile 是最被低估的大型股——是時候購買了嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Nektar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Nektar Therapeutics 嗎？</h2>
</div><p>Before you consider Nektar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Nektar Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Nektar Therapeutics 並不在名單上。</p>
</div><p>While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Nektar Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內克塔治療公司（NASDAQ:NKTR）公佈了財報，每股收益超出預期 1.00 美元